Evidence map›Paper›PMID 32201060›Full record

ArticleUrologic oncology2020

Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery.

Karlijn de Joode, Jolanda I de Ruig-Spakman, Sarwan S Baktawar, Geert J L H van Leenders, Paul C M S Verhagen, Astrid A M van der Veldt

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Urologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karlijn de JoodeDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Jolanda I de Ruig-SpakmanDepartment of Urology, Erasmus MC, Rotterdam, The Netherlands.
Sarwan S BaktawarDepartment of Urology, Erasmus MC, Rotterdam, The Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus MC, Rotterdam, The Netherlands.
Paul C M S VerhagenDepartment of Urology, Erasmus MC, Rotterdam, The Netherlands.
Astrid A M van der VeldtDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address: a.vanderveldt@erasmusmc.nl.
Erasmus MC · NLErasmus University Rotterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansIpilimumabNeoadjuvant TherapyNephrectomyNivolumabTreatment OutcomeIpilimumabNivolumab

Identifiers

PMID32201060
OpenAlexW3012278509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.